IMARC Group's report titled "Newborn Screening Market Report by Product (Instruments, Reagents), Technology (Tandem Mass Spectrometry, Pulse Oximetry, Enzyme Based Assay, DNA Assay, Electrophoresis, and Others), Test Type (Dry Blood Spot Test, CCHD, Hearing Screen), and Region 2025-2033", The global newborn screening market size reached USD 1,089.3 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,818.1 Million by 2033, exhibiting a growth rate (CAGR) of 5.9% during 2025-2033.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/newborn-screening-market/requestsample
Factors Affecting the Growth of the Newborn Screening Industry:
- Increasing Awareness About Early Diagnosis:
More parents and caregivers are realizing early diagnosis is crucial for identifying serious, symptomless conditions. This has led to a higher demand for newborn screening programs. Increased awareness also boosts advocacy from health organizations, non-profits, and community groups. They promote newborn screening, influencing policies and expanding programs.
- Government Initiatives and Policies:
Many governments now require hospitals to screen newborns for certain disorders. This includes genetic, metabolic, and congenital conditions. These mandates ensure screenings are consistent and widespread. Funding from the government supports these programs. It helps improve technology, train professionals, and expand services to underserved areas.
- Technological Advancements:
New technologies like mass spectrometry, DNA sequencing, and PCR are improving newborn screening tests. They make these tests more accurate and sensitive. Now, these tests can detect more disorders precisely. Expanded panels can identify various genetic, metabolic, and congenital conditions from just one blood sample. This early detection leads to better management and treatment outcomes.
We explore the factors propelling the newborn screening market growth, including technological advancements, consumer behaviors, and regulatory changes.
Leading Companies Operating in the Global Newborn Screening Industry:
- Agilent Technologies Inc.
- Baebies Inc.
- Bio-RAD Laboratories Inc.
- Chromsystems Instruments & Chemicals GmbH
- Danaher Corporation
- Masimo Corporation
- Medtronic plc
- Natus Medical Incorporated
- Perkinelmer Inc.
- RECIPE Chemicals + Instruments GmbH
- Thermo Fisher Scientific Inc.
- Trivitron Healthcare
- Waters Corporation
Newborn Screening Market Report Segmentation:
By Product:
- Instruments
- Reagents
Instruments represent the largest segment due to their essential role in performing and automating various screening tests.
By Technology:
- Tandem Mass Spectrometry
- Pulse Oximetry
- Enzyme Based Assay
- DNA Assay
- Electrophoresis
- Others
Tandem mass spectrometry accounts for the majority of the market share because of its high accuracy and ability to screen for multiple conditions simultaneously from a single sample.
By Test Type:
- Dry Blood Spot Test
- CCHD
- Hearing Screen
Dry blood spot test exhibits a clear dominance in the market owing to its simplicity, cost-effectiveness, and ability to collect and store samples efficiently.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America enjoys the leading position in the newborn screening market on account of its advanced healthcare infrastructure, extensive screening programs, and strong government support for early detection initiatives.
Global Newborn Screening Market Trends:
The trend to widen newborn screening is growing. This is due to better technology and the value of early diagnosis. Tools like tandem mass spectrometry and next-gen sequencing are making screenings more accurate and efficient. Moreover, combining screenings with digital health solutions, like electronic health records and telemedicine, is boosting data management and access. Now, many countries are starting or expanding mandatory newborn screenings. They are supported by government funding and policies aimed at better public health.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
